Morphologic and functional imaging of malignant pleural mesothelioma

European Journal of Radiology

Volumn 64, Issue 3, 2007, Pages 356-366

  Yamamuro, Masaki ^a   Gerbaudo, Victor H ^a   Gill, Ritu R ^a   Jacobson, Francine L ^a   Sugarbaker, David J ^a   Hatabu, Hiroto ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; CT; Malignant pleural mesothelioma; MRI; Perfusion; PET; Staging

Indexed keywords

BIOLOGICAL ORGANS; CELL CULTURE; ENDOTHELIAL CELLS; PATIENT MONITORING; RADIATION EFFECTS; TUMORS;

ANGIOGENESIS; MALIGNANT PLEURAL MESOTHELIOMA; PERFUSION; STAGING;

MEDICAL IMAGING;

FLUORODEOXYGLUCOSE; IODINATED CONTRAST MEDIUM; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN;

BENIGN TUMOR; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC PROCEDURE; DIAPHRAGM; HUMAN; INTERMETHOD COMPARISON; LUNG PERFUSION; LYMPH NODE METASTASIS; MALIGNANT MESOTHELIOMA; MORPHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; PERITONEUM; PLEURA EFFUSION; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; REVIEW; THORAX WALL; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION;

DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MESOTHELIOMA; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36148942428     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2007.08.010     Document Type: Review

References (61)

1. Robinson B.W., and Lake R.A. Advances in malignant mesothelioma. N Engl J Med 353 15 (2005) 1591-1603
2. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., and Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16 1 (1998) 145-152
3. Zucali P.A., and Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 42 16 (2006) 2706-2714
4. Edwards J.G., Cox G., Andi A., et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85 6 (2001) 863-868
5. Strizzi L., Catalano A., Vianale G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193 4 (2001) 468-475
6. Drevs J., and Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumor agents targeting angiogenesis. J Intern Med 260 6 (2006) 517-529
7. Dazzi H., Hasleton P.S., Thatcher N., Wilkes S., Swindell R., and Chatterjee A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R): relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 61 (1990) 924-926
8. Marzo A.L., Fitzpatrick D.R., Robinson B.W.S., and Scott B. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 57 (1997) 3200-3207
9. Wong L., Zhou J., Anderson D., and Kratzke R.A. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 38 (2002) 131-136
10. Yang C.T., You L., Yeh C.C., et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 92 (2000) 636-641
11. Schipper H., Papp T., Johnen G., et al. Mutational analysis of the nf2 tumor suppressor gene in three subtypes of primary human malignant mesotheliomas. Int J Oncol 22 (2003) 1009-1017
12. Broaddus V.C., Dansen T.B., Abayasiriwardana K.S., et al. Bid mediates apoptotic synergy between tumor necrosis factor related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem 280 (2005) 12486-12493
13. Dhaene K., Wauters J., Weyn B., Timmermans J.P., and van Marck E. Expression profile of telomerase subunits in human pleural mesothelioma. J Pathol 190 (2000) 80-85
14. Ohta Y., Shridhar V., Bright R.K., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81 1 (1999) 54-61
15. Kumar-Singh S., Weyler J., Martin M.J., Vermeulen P.B., and Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 189 1 (1999) 72-78
16. Galffy G., Mohammed K.A., Dowling P.A., Nasreen N., Ward M.J., and Antony V.B. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 59 (1999) 367-371
17. Demirag F., Ünsal E., Yilmaz A., and Çaǧlar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 128 5 (2005) 3382-3387
18. Shih T., and Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28 11 (2006) 1779-1802
19. Byrne M.J., and Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15 2 (2004) 257-260
20. Oxnard G.R., Armato III S.G., and Kindler H.L. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 52 2 (2006) 141-148
21. Kawashima A., and Libshitz H.I. Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR Am J Roentgenol 155 5 (1990) 965-969
22. Sahin A.A., Coplu L., Selcuk Z.T., et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients. AJR Am J Roentgenol 161 3 (1993) 533-537
23. Metintas M., Ucgun I., Elbek O., et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur J Radiol 41 1 (2002) 1-9
24. Roach H.D., Davies G.J., Attanoos R., Crane M., Adams H., and Phillips S. Asbestos: when the dust settles an imaging review of asbestos-related disease. Radiographics 22 (2002) S167-S184
25. Lorenzo B., Feragalli B., Sacco R., Merlino B., and Storto M.L. Malignant pleural disease. Eur J Radiol 34 2 (2000) 98-118
26. Hierholzer J., Luo L., Bittner R.C., et al. MRI and CT in the differential diagnosis of pleural disease. Chest 118 3 (2000) 604-609
27. Leung A.N., Muller N.L., and Miller R.R. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 154 3 (1990) 487-492
28. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108 4 (1995) 1122-1128
29. Patz E.F., Rusch V.W., and Heelan R. The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging. Am J Roentgenol 166 2 (1996) 323-327
30. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117 1 (1999) 54-63
31. Patz E.F., Shaffer K., Piwnica-Worms D.R., et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 159 5 (1992) 961-966
32. Wang Z.J., Reddy G.P., Gotway M.B., et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 24 1 (2004) 105-119
33. Ding B., Ling H.W., Chen K.M., Jiang H., and Zhu Y.B. Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging. Neuroradiology 48 10 (2006) 773-781
34. Giesel F.L., Bischoff H., von Tengg-Kobligk H., et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest 129 6 (2006) 1570-1576
35. Heelan R.T., Rusch V.W., Begg C.B., Panicek D.M., Caravelli J.F., and Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 172 4 (1999) 1039-1047
36. Knuuttila A., Kivisaari L., Kivisaari A., et al. Evaluation of pleural disease using MR and CT. With special reference to malignant pleural mesothelioma. Acta Radiol 42 5 (2001) 502-507
37. Brix G., Semmler W., Port R., Schad L.R., Layer G., and Lorenz W. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15 4 (1991) 621-628
38. Hatabu H., Gaa J., Kim D., Li W., Prasad P.V., and Edelman R.R. Pulmonary perfusion: quantitative assessment with dynamic contrast-enhanced MRI using ultra-short TE and invasion recovery turbo FLASH. Magn Reson Med 36 (1996) 503-508
39. Ohno Y., Hatabu H., Takenaka D., Adachi S., Kono M., and Sugimura K. Solitary pulmonary nodules; potential role of dynamic MR imaging in management - initial experience. Radiology 224 (2002) 503-511
40. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24 (2006) 3293-3298
41. Warburg O., Posener K., and Negelein E. The metabolism of the carcinoma cell. In: Warburg O. (Ed). The metabolism of tumors (1931), Richard R. Smith, Inc., New York, NY 129-169
42. Bénard F., Sterman D., Smith R.J., Kaiser L.R., Albelda S.M., and Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114 3 (1998) 713-722
43. Schneider D.B., Clary-Macy C., Challa S., et al. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 120 (2000) 128-133
44. 18F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med 43 (2002) 1144-1149
45. Bury T., Paulus P., Dowlati A., Corhay J.L., Rigo P., and Radermecker M.F. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax 52 (1997) 187-189
46. Gerbaudo V.H., Britz-Cunningham S., Sugarbaker D.J., and Treves S.T. Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. Thorax 58 12 (2003) 1077-1082
47. Kinahan P.E., Townsend D.W., Beyer T., and Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25 10 (1998) 2046-2053
48. Beyer T., Townsend D.W., Brun T., et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 41 8 (2000) 1369-1379
49. Townsend D.W., and Cherry S.R. Combining anatomy and function: the path to true image fusion. Eur Radiol 11 10 (2001) 1968-1974
50. von Schulthess G.K., Steinert H.C., and Hany T.F. Integrated PET/CT: current applications and future directions. Radiology 238 2 (2006) 405-422
51. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
52. Antoch G., Stattaus J., Nemat A.T., et al. Nonsmall cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229 2 (2003) 526-533
53. Erasmus J.J., Truong M.T., Smythe W.R., et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 129 6 (2005) 1364-1370
54. Gerbaudo V.H. 18F-FDG imaging of malignant pleural mesothelioma: scientiam impendere vero. Nucl Med Commun 24 6 (2003) 609-614
55. Sugarbaker D.J., Strauss G.M., Lynch T.J., et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11 (1993) 1172-1178
56. Gerbaudo V.H., Mamede M., Trotman-Dickenson B., Bueno R., and Sugarbaker D.J. PET/CT patterns of treatment failure of malignant pleural mesothelioma. J Nucl Med 48 (2007) 360 (abs)
57. Bénard F., Sterman D., Smith R.J., Kaiser L.R., Albelda S.M., and Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40 8 (1999) 1241-1245
58. Flores R.M., Akhurst T., Gonen M., et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 132 4 (2006) 763-768
59. Ceresoli G.L., Chiti A., Zucali P.A., et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F] fluorodeoxyglucose. J Clin Oncol 24 28 (2006) 4587-4593
60. Kono R., Fujimoto K., Terasaki H., et al. Dynamic MRI of solitary pulmonary nodules: comparison of enhancement patterns of malignant and benign small peripheral lung lesions. Am J Roentgenol 188 1 (2007) 26-36
61. Collingridge D.R., Carroll V.A., Glaser M., et al. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62 (2002) 5912-5919